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Abstract
Genome-wide association studies (GWAS) have quickly become the norm in dissecting the genetic
basis of complex diseases. Family-based association approaches have the advantages of being robust
to possible hidden population structure in samples. Most of these methods were developed with
limited markers. Their applicability and performance for GWAS need to be examined. In this
report, we evaluated the properties of the family-based association method implemented by
ASSOC in the S.A.G.E package using the simulated data sets for the Framingham Heart Study, and
found that ASSOC is a highly useful tool for GWAS.
Background
Genome-wide association studies (GWAS) are gaining
popularity in genetic analysis of complex traits with the
development of genotyping technology at the genome
level. With genetic information at millions of single-
nucleotide polymorphisms (SNPs) and other genetic
markers, such studies offer great opportunities and also
present challenges in developing appropriate statistical
analysis methods. The data distributed by Genetic
Analysis Workshop 16 provides a great opportunity to
examine the strengths and limitations of current statis-
tical methods for GWAS.
Many GWAS have been reported in the literature and
many more are being performed. Most of them are
population-based association studies and use designs
such as case-control studies. Such designs have the
advantages that samples are easy to ascertain and that
results have relatively high power when analyses are
carried out properly. However, it has been shown that
population-based approaches, such as case-control stu-
dies, can produce spurious associations in the presence
of population substructure, especially in large-scale
studies at the genomic level [1,2]. An alternative
approach is to use the family-based association methods,
such as the transmission-disequilibrium test [3], the
family-based association test (FBAT) [4], and a regres-
sion method [5] implemented by ASSOC in the S.A.G.E.
package. These methods are robust to population
substructure and other cryptic relatedness in the samples.
However, these methods have been proposed in the era
with only a few genetic markers and are intended mostly
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performance for GWAS has not been examined. The
simulated data set of the Framingham Heart Study (FHS)
provides both the family structure and the genotype
information at genome-wide SNPs. The underlying
simulation models are also provided. It is the purpose
of this study to evaluate the performance of the family-
based association method implemented by ASSOC in
analyzing GWAS.
Methods
ASSOC implements a regression method that tests for
association between a continuous trait and one or more
covariates, including genetic markers from extended
family data, and accounts for familial correlations [5].
The program estimates the parameters of a baseline
model and those of alternate models that include
specific sets of covariates. A likelihood-ratio test is then
performed to evaluate the significance of the covariates.
The FHS simulated data set includes 6,476 subjects with
both phenotype and genotype data in 942 pedigrees of
up to three generations and 188 singletons. We excluded
the singletons from our analysis because they do not
have family information. The simulated data contain
200 replicates of the phenotypes. We used the phenotype
data from the first replicate. Pedigree files were con-
structed from the supplied ‘triplet_sim’ file and merged
with phenotype and genotype data. In addition to each
of the SNPs, we included subject’sa g e ,s m o k i n gs t a t u s ,
diet, and lipid-lowering drug usage as covariates. We
kept all family members in the analysis because ASSOC
could account for the familial correlations. We chose to
test the association of HDL with all the makers from
chromosome 19 in the 50 k panel and 500 k panel
b e c a u s et h e r ea r et w om a j o rg e n e sf o rH D Lo n
chromosome 19. In all, there are 1,639 markers in the
50 k panel and 6,350 markers on 500 k panel on
chromosome 19. We assumed an additive model for all
the markers. The program was run in a batch mode so
that it would test for the association of the SNPs
successively in one run. From the simulation model,
there are five major genes for HDL. Two were on
chromosome 19, and the other three were from
chromosomes 8, 9, and 15, respectively. The chromo-
some locations of the five major genes were given in
T a b l e1 .W et e s t e dt h ea s s o c i a t i o no fH D Lw i t ha l lt h e
five major genes. There are a total of 1,000 polygenes for
HDL, among which 15 are on chromosome 19.
Results
We performed association tests of all 1,639 markers on
chromosome 19 with simulated HDL data. Out of 1,639
markers, the tests of 18 markers were significant at the
0.01 level. Because the HDL data were simulated using
the markers in the 500 k panel and not the markers in
the 50 k panel, and since the markers in the two panels
are not close, we assume that the markers in the 50 k
panel did not contribute to the HDL phenotype. The
significance result reflects false positives. Therefore, our
results give an empirical type I error probability of 0.011,
which agrees well with the nominal level of 0.01.
We further tested the association of the five SNPs
representing the major genes with HDL (Table 1). They
were all significant at 0.05 level regardless of the mode of
inheritance and heritability. The true genetic models are
additive for rs8103444, rs8035006, and rs8192719, and
dominant for rs10820738 and rsrs3200218. However, if
more stringent significance level were used for genome-
wide studies, only two markers, rs10820738 and
rs3200218, were found significant at 10
-6 level. Table 1
also gives the estimated effect size for the five SNPs. SNP
rs10820738 has the largest effect size, which is consistent
with the simulation model in which it has the largest
heritability.
We then tested all 6,350 SNP markers on chromosome
19 in the 500 k panel for association with the simulated
HDL data. Among the 15 markers that have polygenic
effects on chromosome 19, association tests at six
markers were significant at the 0.05 level (Table 2). The
marker positions in base pairs are also given in Table 2.
The pairwise LD was relatively low, with a maximum r
2
of 0.003 as computed with Haploview [6]. A total of 395
tests were significant at 0.05 level for all the 6,350
markers tested on chromosome 19. Excluding the two
major genes and six polygenes that are truly associated
Table 1: Test results of the 5 SNPs from 500 k panel for major gene effects of HDL
Model Location Intercept Diet Sex Rx
a Age Smoke
b SNP SE p-Value
rs10820738 9q31.1 68.694 0.028 13.565 1.486 0.019 0.714 4.524 0.518 3.20 × 10
-18
rs3200218 8p22 68.680 0.027 13.552 1.420 0.020 0.664 -1.671 0.319 1.63 × 10
-7
rs8035006 15q21 68.684 0.023 13.527 1.474 0.020 0.647 0.831 0.284 0.003
rs8192719 19q13.2 68.689 0.021 13.524 1.470 0.020 0.666 -0.821 0.306 0.007
rs8103444 19113.2 68.686 0.021 13.533 1.452 0.019 0.660 0.629 0.305 0.039
aRx, lipid lowering drug use.
bSmoke, smoking status.
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error rate of 0.06. Figure 1 gives the quantile-quantile
plot of the p-values for all the null markers. The observed
distribution fits well with the expected uniform distribu-
tion and there is no major inflation of type I error.
A m o n gt h et o p5 0S N P sr a n k e db yp-values, four SNPs
are true findings with polygenic effects.
We also applied FBAT to test the association of HDL with
all 6,350 SNPs on chromosome 19. A total of 325 tests
are significant at 0.05 level. However, only two
polygenes are true positives (rs10420985 and
rs599458, with p-values 0.004408 and 0.028563, respec-
tively). None of the major genes was significant with
FBAT. Nonetheless, the type I error rate seems well
controlled.
Discussion
Family-based association methods are appealing alter-
natives for the population-based case-control design
because they are robust to population stratification in
the samples. Several such methods have been proposed.
However, they were all proposed before the current
genomic era. As the norm of the field moves to GWAS,
the performance and applicability of these methods need
to be examined for GWAS. In this report, we examined
the performance of a regression-based method [5],
implemented in the program ASSOC in the software
package S.A.G.E., using the simulated HDL data in the
Framingham Heart Study. Based on the results of the
tests with the markers on chromosome 19 in the 50 k
panel, we found that ASSOC gives the correct type I error
rate. When applied to the markers on chromosome 19 in
the 500 k panel (tests performed at 0.05 level), the
empirical type I error rate was 0.06, which is slightly
inflated. The reason could be that there is linkage
disequilibrium between the markers in the causal genes
and markers close by, and when we estimated type I error
rate, we only excluded the markers in the causal genes
with either major or polygenic effects and not those
markers in linkage disequilibrium. Therefore, as a
general conclusion, ASSOC gives a more-or-less the
correct type I error rate, and hence is a valid test for
GWAS.
In our analysis, ASSOC detected all five major genes and
six of the 15 polygenes for HDL on chromosome 19. In
contrast, FBAT detected only two of the 15 polygenes
and none of the major genes on chromosome 19. It
should be noted that the data may be too limited to give
Table 2: Test results among polygenes affecting HDL on chromosome 19
Model Position Intercept Diet Sex Rx
a Age Smoke
b SNP SE p-Value
rs10420985 62,077,748 68.693 0.017 13.519 1.508 0.020 0.656 -1.693 0.457 0.000214
rs8182590 13,282,550 68.691 0.029 13.542 1.478 0.019 0.686 -0.973 0.263 0.000222
rs35150881 2,572,193 68.689 0.023 13.537 1.449 0.019 0.663 -1.727 0.550 0.0017
rs8107007 33,248,124 68.691 0.022 13.548 1.454 0.020 0.651 1.683 0.537 0.001723
rs10403702 44,840,424 68.692 0.021 13.532 1.491 0.020 0.647 5.564 2.199 0.011418
rs7251886 46,880,615 68.687 0.020 13.537 1.501 0.020 0.669 -0.666 0.266 0.012645
rs11673050 35,535,929 68.690 0.019 13.530 1.473 0.020 0.659 -0.505 0.279 0.069854
rs2277987 8,458,273 68.689 0.021 13.549 1.480 0.020 0.658 0.496 0.289 0.08626
rs16989305 49,579,243 68.689 0.023 13.540 1.482 0.020 0.666 4.904 3.111 0.115021
rs16966229 36,924,150 68.687 0.021 13.530 1.461 0.020 0.660 -2.165 1.381 0.117801
rs17620029 24,146,152 68.690 0.019 13.539 1.465 0.020 0.652 -0.390 0.369 0.291036
rs3786501 49,691,015 68.691 0.021 13.536 1.473 0.020 0.656 0.217 0.314 0.490909
rs11085876 13,947,513 68.689 0.020 13.540 1.467 0.020 0.655 -0.164 0.273 0.547852
rs17716486 34,455,727 68.690 0.020 13.539 1.478 0.020 0.655 -0.204 0.376 0.586957
rs599458 20,792,763 68.689 0.021 13.538 1.473 0.020 0.657 0.082 0.454 0.856762
aRx, lipid lowering drug use.
bSmoke, smoking status.
Figure 1
Quantile-quantile plot of the p-values from null
markers.
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encouraging to see that ASSOC could detect one of the
polygenes, rs10403702, whose minor allele frequency is
only 0.35%. Current association studies generally focus
on common SNPs (e.g., SNPs with minor allele
frequency > 5%) based on the common disease,
common variants hypothesis [7-10]. The other reason
is that the statistical power may not be sufficient for rare
SNPs when the sample size is limited. However, recent
development in genotyping technology allows efficient
genotyping in large samples and there is a call for
shifting the paradigm of association studies to rare SNPs
because it may be more effective to discover suscept-
ibility genes for common diseases [11].
In conclusion, the method implemented in ASSOC
provides a valid association test for family-based data
and is reasonably powerful approach to be applied in
GWAS. However, it should be noted that it is also a
rather slow method. In our analysis, it took around 10
minutes to test one marker in our Windows-based
workstation with 2.13 GHz CPU. It will take substantial
amount of time to perform the test for millions of
markers in GWAS. Parallel computing would be the
solution.
Conclusion
Using the simulated data for the Framingham Heart
Study, we found the family-based regression method
George et al. [5] implemented in ASSOC in the S.A.G.E.
software is applicable to GWAS. It provides the correct
type I error rate and reasonable power. However, this
method is computationally time-consuming.
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